⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VIR News
Vir Biotechnology, Inc. Common Stock
TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Outlook 2026-2030 with Focus on US, China, South Korea, Australia, and Europe - ResearchAndMarkets.com
businesswire.com
GILD
MRK
CGEN
VIR
TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Report 2026-2030: Roche, Gilead Sciences, Merck, Arcus Biosciences, Compugen, and Vir Biotechnology Advance Deep Oncology Pipelines
globenewswire.com
GILD
MRK
ARCX
CGEN
VIR
Vir Biotechnology to Present at the 44 th Annual J.P. Morgan Healthcare Conference
businesswire.com
VIR
Norgine enrichit son portefeuille d'hépatologie et de spécialités grâce à un accord de licence exclusif avec Vir Biotechnology USA - Français USA - English USA - English USA - Deutsch Italia - Italiano USA - español
prnewswire.com
VIR
ALNY
Norgine mejora su cartera de productos de hepatología y especialidades USA - español USA - Deutsch Italia - Italiano USA - English USA - English
prnewswire.com
VIR
ALNY
Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung mit Vir Biotechnology USA - Deutsch USA - English USA - English
prnewswire.com
VIR
ALNY
Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology USA - English USA - English
prnewswire.com
VIR
ALNY
Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology USA - English USA - English
prnewswire.com
VIR
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
businesswire.com
VIR
Prostate Cancer Drugs Market to Reach USD 28.10 Billion by 2033 | According to DataM Intelligence
prnewswire.com
BIIB
MRK
JNJ
PFE
AZN
BMY
GILD
EXEL
RDVY
CRIS
VRTX
INCY
ABBV
LULU
VIR
FGEN
HALD